These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30268471)

  • 21. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
    Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
    Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials.
    Mohamed H; Eltobgy M; Abdel-Rahman O
    Anticancer Agents Med Chem; 2017; 17(9):1228-1233. PubMed ID: 28042777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
    Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
    Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Photodynamic therapy for lung cancer and malignant pleural mesothelioma.
    Simone CB; Cengel KA
    Semin Oncol; 2014 Dec; 41(6):820-30. PubMed ID: 25499640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?".
    Di Noia V; Vita E; Ferrara M; Strippoli A; Basso M; Schinzari G; Cassano A; Bria E; Barone C; D'Argento E
    Curr Treat Options Oncol; 2019 Feb; 20(3):23. PubMed ID: 30790063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].
    Marco S; Tomasini P; Greillier L; Barlesi F
    Rev Mal Respir; 2011 Dec; 28(10):1216-29. PubMed ID: 22152931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates.
    Schunselaar LM; Monkhorst K; van der Noort V; Wijdeven R; Peters D; Zwart W; Neefjes J; Baas P
    J Thorac Oncol; 2018 Oct; 13(10):1577-1587. PubMed ID: 29959059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Update of pemetrexed in thoracic oncology].
    Brechot JM; Morère JF
    Bull Cancer; 2007; 94 Spec No Actualites():S139-41. PubMed ID: 17845984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Severe complications of systemic treatment in thoracic oncology].
    Berghmans T; Brandão M; Ilzkovitz M; Meert AP
    Rev Mal Respir; 2024 Apr; 41(4):317-324. PubMed ID: 38461088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies.
    Andrini E; Federico AD; Sisi M; Rosellini M; Palladini A; Lamberti G; Giglio A; Gelsomino F
    Immunotherapy; 2022 Nov; 14(16):1329-1340. PubMed ID: 36382476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
    Uramoto H; Onitsuka T; Shimokawa H; Hanagiri T
    Anticancer Res; 2010 Oct; 30(10):4309-15. PubMed ID: 21036757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of bevacizumab in the treatment of malignant pleural mesothelioma.
    Brosseau S; Assoun S; Naltet C; Steinmetz C; Gounant V; Zalcman G
    Future Oncol; 2017 Dec; 13(28):2537-2546. PubMed ID: 29086616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapies currently in Phase II trials for malignant pleural mesothelioma.
    Pinton G; Manente AG; Tavian D; Moro L; Mutti L
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1255-63. PubMed ID: 23815672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proton-coupled folate transporter as a biomarker of outcome to treatment for pleural mesothelioma.
    Petri GL; Cascioferro S; Parrino B; Peters GJ; Diana P; Giovannetti E
    Pharmacogenomics; 2018 Jul; 19(10):811-814. PubMed ID: 29916298
    [No Abstract]   [Full Text] [Related]  

  • 36. Searching for targets for the systemic therapy of mesothelioma.
    Stahel RA; Weder W; Felley-Bosco E; Petrausch U; Curioni-Fontecedro A; Schmitt-Opitz I; Peters S
    Ann Oncol; 2015 Aug; 26(8):1649-60. PubMed ID: 25722383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pioneering the Way: The Revolutionary Potential of Antibody-Drug Conjugates in NSCLC.
    Chen X; Zeng C
    Curr Treat Options Oncol; 2024 Apr; 25(4):556-584. PubMed ID: 38520605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
    Remon J; Reguart N; Corral J; Lianes P
    Cancer Treat Rev; 2015 Jan; 41(1):27-34. PubMed ID: 25467107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer].
    Wang N; Zhao L; Zhang D; Jia Y; Kong F
    Zhongguo Fei Ai Za Zhi; 2022 Mar; 25(3):214-218. PubMed ID: 35340165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody-drug conjugates in advanced lung cancer: Is this a new frontier?
    Reuss JE; Rosner S; Levy BP
    Clin Adv Hematol Oncol; 2024 Jun; 22(5):217-226. PubMed ID: 38805313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.